Studies on molecular biology have considerably enhanced our understanding of congenital coagulation disorders but have failed so far to supply tools for an adequate classification of defects. In fact, mutations in the same domain may give rise to different phenotypes. Conversely, mutations in different domains, controlled by different exons, may cause similar patterns. The 37 kindreds with congenital factor X (FX) deficiency, known to have a defect in the catalytic domain, have been evaluated in an attempt to investigate the genotypeÀphenotype relation. Discrepant results were obtained because about half kindreds showed a type I pattern, namely a concomitant decrease in FX activity and antigen. The other half showed a type II pattern, namely a decrease in FX activity with a normal or near normal FX antigen. In a few instances, the allocation of the kindred either to type I or to type II defect could not be reached, due to the lack of information about the antigen.
Introduction
Molecular biology techniques introduced in the late 80s for the study of congenital coagulation disorders were greeted with great satisfaction. It was thought that, finally, we could explain all hereditary patterns, establish a firm genotype-phenotype relation, and propose a satisfactory classification of all coagulation defects. The progress was immense. However, it was subsequently acknowledged that the picture has not been completely clarified as yet. Congenital Factor X (FX) deficiency is one of the rarest coagulation disorders, but a very important one because of the pivotal role played by FX in both the intrinsic and extrinsic systems. [1] [2] [3] The gene-controlling FX synthesis is located on the long arm of chromosome 13 at 13q34, close to the gene controlling factor VII (FVII). The gene contains 8 exons and 7 introns. Each exon encodes a specific domain. The most important are exon 11 and exons 7 and 8, which encode the g-carboxylase-rich domain and the active serum protease domain, respectively.
It has recently been demonstrated that kindreds that show a predominant or an exclusive defect in the extrinsic system showed different mutations involving different exons. 4 The same was true for kindreds that showed a predominant or exclusive defect in the intrinsic system. 1, 4 Furthermore, it was shown that kindreds that showed normal Russell's Viper Venom (RVV)derived clotting tests could be associated with different mutations in different exons. 5 This indicated, contrary to the widely held assumption, that reactivity toward different activating reagents did not depend on a specific exon or area.
Because of all these discrepancies, a satisfactory classification of congenital FX defects based on molecular biology studies still eludes us. The classification based on type I defects (cases of true deficiency namely with a concomitant decrease of FX activity and antigen) and type II defects (cases with low activity but normal or near normal antigen) is still acceptable.
The purpose of the current study was to investigate the genotype-phenotype pattern in kindreds with defects in the catalytic area in an attempt to find whether there are grounds for a suited classification of these defects.
Material and Methods
All families with FX deficiency and a defect in the catalytic area have been carefully evaluated. Original articles, regardless of the language, were obtained with the cooperation of the Pinali Library of the Padua University School of Medicine and through the courtesy of Acta Med Service, Sorengo; Switzerland. 2, 3, Kindreds that showed a double defect, both in the catalytic domain and in another area, have not been taken into consideration.
Kindred with homozygous, heterozygous, or compound heterozygous defects have all been analyzed. However, patients with a compound heterozygosity were included only if both defects involved the catalytic domain; otherwise they were excluded ( Figure 1 ).
Besides the molecular defects, FX activity levels obtained by different methods, namely extrinsic, intrinsic, RVV dependent, and chromogenic, have been recorded. Factor X activity assay was carried out using a FX-deficient plasma as substrate and a tissue thromboplastin or a partial thromboplastin (cephalin) as activating agents. In the case of RVV clotting assays, the substrate was either a congenitaldeficient plasma or a factor VII-deficient and factor X-deficient artificially depleted plasma.
Factor X antigen levels were determined using electroimmunoassay or enzyme-linked immunosorbent assay (ELISA) methods. The bleeding tendency was classified as mild, moderate, or severe, according to the statements and conclusions made by the authors of the single articles. In fact it was impossible, on the basis of the clinical information supplied, to reach any other independent evaluation of the severity of bleeding manifestation.
Both, Kindreds that showed a type I pattern, namely a concomitant decrease in activity and antigen (cross-reactive material negative), and kindreds with a type II pattern, namely with low activity and normal or near normal antigen (cross-reactive material positive), were studied. Eponymous or letters as proposed by the authors of the single articles were used to distinguish the different kindreds. Kindreds without an eponym have been attributed one by us according to the geographical background of the family, or, alternatively, according to the city where they were first studied.
Results
At least 37 kindreds met the selection criteria (Table 1) . Several exons and residues were involved. Sixteen kindreds belonged to type I defect (Cross Reactive Material (CRM) negative), whereas 15 kindreds could be assigned to type II (CRM positive). In 6 instances, no FX antigen was reported and therefore no sure allocation could be made. There was no appreciable difference in the rate of type I or II defects according to the position of the residue involved. Furthermore, no particular amino acid substitution was associated with a prevalence of either type I or type II defect. The same mutation (Cys350Phe) was seen in 2 families. Furthermore, the same was true for Gly222Asp and Ile411Phe mutations. Finally, the mutation Ser334Pro was seen in 2 instances at the homozygous level and in 1 instance in a compound heterozygosity.
Bleeding tendency, as judged by the authors of single articles, was mild in 6 cases, moderate in 6 cases, and severe in 14 cases. In 5 cases, the patient appeared asymptomatic. In 5 instances, no clinical observation as to the bleeding tendency was reported and therefore these patients could not be classified. Altogether there was a good correlation between bleeding diathesis and FX level. All patients with severe bleeding manifestations had FX level via the extrinsic and/or the intrinsic system of 1% to 2% normal. Most asymptomatic patients were heterozygotes (FX level around 50%).
Discussion
FX is synthesized in the liver as a single chain vitamin K-dependent protein. It circulates in the plasma at a concentration of about 1 mg/mL as a 2-chain molecule. The light chain has 139 residues and contains the Glutamic Acid (Gla) domain, the aromatic stack, and the Epidermal Growth Factor (EGF) domain.
The heavy chain has 346 residues and contains the activation peptide and the catalytic domain. The 2 chains of the circulating FX are bound together by a disulfide bond (residues Cys 89 and Cys 124) and by a tripeptide Arg-Lys-Arg (residues 139-142). The catalytic domain of FX is composed of 294 residues of the heavy chain. It is controlled, in part, by exons 6, 7, and, especially, by exon 8. 1 To avoid interferences, the probands who showed a defect both in the catalytic and in another area have been eliminated from the general considerations. In fact the second molecular alteration Figure 1 . File of mutations in cases of factor X (FX) deficiency with a defect in the catalytic domain. For reasons of clarity, only kindreds with homozygous mutations in the catalytic domain are taken into consideration. Putative structure of FX is that proposed and used by Greenberg and Davie. 35 The site of mutations for compound heterozygotes or for heterozygotes can be easily inferred by taking into account the sites indicated here for homozygotes. could influence the pattern. However, even for the kindreds with a defect only in the catalytic domain, the discrepancies remain great and unexplained. The kindreds could be divided into those with a concomitant lack of FX activity and FX antigen and into those with low FX activity and normal or near normal FX antigen. The latter group is to be further subdivided into cases with inert CRM, regardless of the activation system, and into those with different reactivity (eg, FX Friuli, FX Rome) in the different assay systems, extrinsic, intrinsic, and RVV dependent. 13, 15, 20, 25 It is not easily explainable why some patients with mutations in this domain show equivalent reduction in both FX activity and antigen, whereas others show a clear discrepancy between activity and antigen level. The most likely explanation is a difference in the secretion of the molecule from the hepatocytes, depending on the residue involved; however, this remains to be proven.
In some cases, there is no secretion; in other cases, a release is present but the secreted molecule cannot be properly activated. This is even more surprising, because in general, cases of ''true'' deficiency are usually due to mutation in the prepro leader sequence. This has been demonstrated to be the case for other vitamin K-dependent clotting factors. 36 Possible explanations for the discrepancies could be (1) errors in clotting and antigen assays; (2) failure to recognize the existence of a second molecular abnormality; and (3) existence of a still undefined controlling mechanism. Point 1 seems unlikely because clotting and immunological assays of FX are fairly well-defined procedures.
Point 2 also seems remote because expression studies carried out in a few families have always yielded results compatible with mutation studies. Nothing can be said yet with regard to point 3. In conclusion, the discrepancies seen between phenotype and genotype in kindreds with FX deficiency involving mutations in the catalytic domain remain so far unexplained.
Putative crystallographic models or reconstructions may be useful but not yet univocal. The comparison of phenotypes of the same mutation as studied by different researchers is not always possible for lack of some clotting or immunological data. However, in the case of the Gly 222 Asp or of the Ile 412 Phe mutations, found in the 2 kindreds at the homozygous level, similar or equivalent results were observed ( Table 2) . Unfortunately, the number of families in which the same mutation was found by different or by the same authors is still limited. Therefore, no definite conclusion can be drawn. This indicates the need to deal with single mutations and not with the entire domain or area. The specificity of the mutation is of paramount importance because even similar mutations in a closed area of a domain may yield different phenotypes. To define a mutation as pertaining to the catalytic domain is not sufficient and may be misleading because there is no typical phenotypic pattern for mutations in this domain.
The critical review once again underscores the fact that congenital coagulation bleeding disorders are always to be approached in a global or multipronged manner. Isolated molecular biology studies are not sufficient, because they cannot surely predict the phenotype. Needless to say, clotting and antigen assays alone are also insufficient. The discrepancies in the reported results are at the basis of the difficulties in formulating an adequate classification of the defect. A classification based only on molecular biology studies will indicate the site of the mutation (heavy chain, light chain, activation peptide, etc) but would fail to predict the activityÀantigen ratio present in these patients and the behaviour of the FX antigen in different assay systems. The only group of patients who seem to have a fairly constant phenotype are those that show a defect in the Gla domain. 37 This is probably due to the small size of the Gla domain (32 residues) in comparison with the catalytic domain (about 300 residues).
